Comparison · NCT04308590-bdffe9d6
Relacorilant vs Placebo: Number of Patients With Any Dose Increase or Switch in Antihypertensive Medication
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Relacorilant vs Placebo: Number of Patients With Any Dose Increase or Switch in Antihypertensive Medication. Trial comparisons, record NCT04308590-bdffe9d6. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04308590-bdffe9d6
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0455 | 0.00807 | 0.218 | wilson | |
| Risk in group 2 | 0.152 | 0.0665 | 0.309 | wilson | |
| Risk difference, group 1 minus group 2 | -0.106 | -0.268 | 0.0863 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.3 | 0.0375 | 2.4 | log | |
| Odds ratio, group 1 over group 2 | 0.267 | 0.029 | 2.46 | log | |
| Number needed to treat, for one fewer participant with the outcome on Relacorilant than on Placebo | 9.43 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Relacorilant | Patients will receive relacorilant increased sequentially from 100 mg once daily to a maximum dose of 400 mg once daily. | 1 | 22 | OG000 |
| Group 2 | Placebo | Patients will receive placebo matched to study drug once daily. | 5 | 33 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Patients With Any Dose Increase or Switch in Antihypertensive Medication
- Description
- Time frame
- Baseline and Week 22
- Population
The analysis population was patients in the ITT Population who had HTN with or without DM/IGT at Baseline, received antihypertension medication both at Baseline and postbaseline, and had an available assessment at Week 22.
Source ClinicalTrials.gov
Trial
- Title
- A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
- NCT number
- NCT04308590
- Phases
- PHASE3
- Conditions
- Hypercortisolism
- Interventions
- Relacorilant, Placebo
- Lead sponsor
- Corcept Therapeutics
- Results first posted
- 2025-08-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04308590?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04308590-bdffe9d6